Praktické lekárnictvo 4/2017
Infliximab
Infliximab is the first monoclonal antibody directed to TNFα.Used in the treatment of rheumatoid arthritis or other arthritis, inflammatory bowel diseases and psoriasis.Infliximab is administered by slow intravenous infusion, typically at doses of 3–5 mg / kg at intervals of 1 - 8 weeks.It is slowly eliminated from the body with a half - life of 7–12 days.For its high effectiveness and safety is a targeted first - line treatment of these diseases.Its side effects include especially infusion reactions and the risk of opportunistic infections, other adverse reactions are generally mild or infrequent.
Keywords: infliximab, pharmacodynamics, pharmacokinetics, clinical use, adverse effects
